Evaluating transgene delivery in human organoid models to select AAV capsids

There are promising results in treating genetic disorders found in introducing modified genetic material into tissue or cells, known as gene therapy, and recombinant adeno-associated viruses (AAVS).

Evaluating transgene delivery in human organoid models to select AAV capsidsImage Credit: ACROBiosystems

AAV capsids act as a guide while moving genetic material into host cells and tissue. Research has shown that AAV serotypes are developed concurrently to identify the best subtype for preclinical and clinical use.

There has been limited success found in clinical practices of gene therapy, potentially due to the variable effectiveness of transgene delivery between in vitro/in vivo models and humans.

This study mimics human physiology in an organoid-based approach with organ-specific features and cell diversity within the organ.

Organoids provide a more in-depth model than traditional 2D cell cultures by modeling cell signaling, cell-extracellular and cell-cell matrix interactions to better simulate the intricate balance between varying cell types and their functions.

This study used RNA sequencing to verify several human-based organoid models by identifying known marker genes. The transgene efficacy was evaluated through five AAV serotypes on each organoid model.

A comparison of the expression of delivered GFP transgene between each organoid was used to assess transduction to select the optimal AAV serotype.

This research shows improved preclinical modeling in using human organoid models when selecting AAV serotypes and evaluating the effectiveness of transgene delivery. This provides better guidance for gene therapy development when advancing into clinical research.

Read the full app note

About ACROBiosystems

ACROBiosystems is a cornerstone enterprise of the pharmaceutical and biotechnology industries. Their mission is to help overcome challenges with innovative tools and solutions from discovery to the clinic. They supply life science tools designed to be used in discovery research and scalable to the clinical phase and beyond. By consistently adapting to new regulatory challenges and guidelines, ACROBiosystems delivers solutions, whether it comes through recombinant proteins, antibodies, assay kits, GMP-grade reagents, or custom services. ACROBiosystems empower scientists and engineers dedicated towards innovation to simplify and accelerate the development of new, better, and more affordable medicine.


Sponsored Content Policy: News-Medical.net publishes articles and related content that may be derived from sources where we have existing commercial relationships, provided such content adds value to the core editorial ethos of News-Medical.Net which is to educate and inform site visitors interested in medical research, science, medical devices and treatments.

Last updated: Jan 27, 2024 at 2:12 AM

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    ACROBiosystems. (2024, January 27). Evaluating transgene delivery in human organoid models to select AAV capsids. News-Medical. Retrieved on May 23, 2024 from https://www.news-medical.net/whitepaper/20231219/Evaluating-transgene-delivery-in-human-organoid-models-to-select-AAV-capsids.aspx.

  • MLA

    ACROBiosystems. "Evaluating transgene delivery in human organoid models to select AAV capsids". News-Medical. 23 May 2024. <https://www.news-medical.net/whitepaper/20231219/Evaluating-transgene-delivery-in-human-organoid-models-to-select-AAV-capsids.aspx>.

  • Chicago

    ACROBiosystems. "Evaluating transgene delivery in human organoid models to select AAV capsids". News-Medical. https://www.news-medical.net/whitepaper/20231219/Evaluating-transgene-delivery-in-human-organoid-models-to-select-AAV-capsids.aspx. (accessed May 23, 2024).

  • Harvard

    ACROBiosystems. 2024. Evaluating transgene delivery in human organoid models to select AAV capsids. News-Medical, viewed 23 May 2024, https://www.news-medical.net/whitepaper/20231219/Evaluating-transgene-delivery-in-human-organoid-models-to-select-AAV-capsids.aspx.

Other White Papers by this Supplier

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.